Partnerships
Kineta has established strategic partnerships to advance the development of our innovative drug programs. We value collaborating with companies and institutions at the forefront of scientific innovation and are interested in building alliances to accelerate the development of next-generation immunotherapies for patients with unmet needs.
To explore partnering opportunities, please contact Kineta
Collaborations
Kineta entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the U.S. and Canada). Under this collaboration, Kineta will evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KVA12123 (formerly KVA12.1), its novel anti-VISTA monoclonal antibody, alone and in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced solid tumors.
Licenses
Kineta entered into a strategic research collaboration and license agreement with Merck (known as MSD outside the U.S. and Canada) focused on accelerating the development of new treatments for neurodegenerative diseases. Kineta announced it will receive a $5 Million milestone payment from Merck in June 2023, triggered by validating an undisclosed target for amyotrophic lateral sclerosis (ALS). Following this milestone, Merck will assume sole responsibility for all future development and commercialization of the ALS program.
Kineta entered into a worldwide, exclusive license agreement with Genentech, a member of the Roche Group, for rights to potential therapeutic small molecule modulators of an undisclosed target.
Kineta entered into a worldwide, exclusive license agreement with Fair Therapeutics for the rights to CFTR Modulators as a potential treatment for cystic fibrosis.